Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

            Therapeutic Area: Endocrinology Product Name: NE3107

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2021

            Details:

            NE3107, a new drug candidate in development for Alzheimer’s and Parkinson’s Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.